Navigation Links
AARP Statement on Governor's Bill for Prescription Drug Marketing Reform and Transparency
Date:5/15/2008

AARP commends Governor Paterson's leadership in proposing prescription drug marketing reform and transparency

ALBANY, N.Y., May 15 /PRNewswire-USNewswire/ -- AARP strongly believes New York has a paramount interest in passing the Governor's prescription marketing reform proposals which address the undue influence that pharmaceutical companies have over prescribing decisions that affect not only consumers' pocket books but the treatment they receive.

The reforms include banning gifts of over $50 (excluding free samples) to doctors and requiring speakers at continuing medical education programs for health professionals to disclose any financial relationships they might have with a drug company.

AARP strongly supports provisions in the proposed legislation to make the business transactions of pharmaceutical benefit managers (PBMs) more transparent in order to drive down the cost of prescription drugs.

We strongly encourage the New York State Legislature to pass this legislation that would help so many New Yorkers before the end of the legislative session. The pharmaceutical industry should not dictate prescription drug policy in our State. The Legislature must reject the opposition from the drug industry and do the right thing for their constituents.

The Governor's bill will increase a New Yorker's ability to access affordable prescription drugs and improve the quality of their healthcare. In addition, this legislation would help all taxpayers who fund public prescription drug programs, such as Medicaid and EPIC.

According to a January 2006 article in the Journal of the American Medical Association (JAMA), titled "Health Industry Practices That Create Conflicts of Interest," approximately 90% of the $21 billion pharmaceutical industry marketing budget continues to be directed at physicians.

When a drug company sales representative walks into a doctor's office armed with gifts and promotes a drug company's newest,
'/>"/>

SOURCE AARP New York
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Statement of Eli Lilly and Company on Dr. David Egilman Settlement:
2. Takeda statement on ACTOS meta-analysis published in the Journal of the American Medical Association
3. Takeda Statement on ACTOS(R) (Pioglitazone HCl) Meta-Analysis Published in the Journal of the American Medical Association
4. Statement by Mike Leavitt Secretary of Health and Human Services on the United States-China Bilateral Meetings on Food and Drug Safety
5. Statement by Oscar S. Wyatt, Jr.
6. Statement from Employment Policies Institute on Senator Hillary Clintons Health Care Plan
7. Pelosi Statement on Proposed Entitlement Task Force
8. Statement by Robert Greenstein, Executive Director of the Center on Budget and Policy Priorities, on the New Congressional SCHIP Agreement
9. Statement on House/Senate Agreement on SCHIP Legislation
10. Statement from the Alliance for Quality Nursing Home Care
11. Produce for Better Health Foundation Releases Statement on Study Saying Fruit & Vegetable Consumption Not Strongly Associated With Colon Cancer Risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2014)... Continuing to meet the skin health needs ... addition of a new doctor and office in Grand ... skin care in Grand Rapids since 1980 is merging ... doctor, my passion is making sure my patients receive ... I’m better able to focus on my patients and ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 "My wife ... of a car accident," said one of two inventors ... strain in her shoulder and neck area. She tried ... reduced pain and pressure, assisting in comfort and providing ... patent-pending PILLOW CRADLE to support the head, neck and ...
(Date:8/30/2014)... Serving contented clients since inception, #1 web design ... is now offering discount for Labor Day on all ... putting forward the best of web development technology before ... of professionals and web developers and designers has expertise ... critical issues of web development and can develop websites ...
(Date:8/30/2014)... August 2014: Transvenous lead extraction (TLE) is clinically successful ... from the European Lead Extraction ConTRolled (ELECTRa) registry presented ... by Dr Maria Grazia Bongiorni, chair of the registry,s ... cardiac implantable electronic devices (CIED) implant procedures has grown ... of complications has increased and leads are often the ...
(Date:8/30/2014)... August 30, 2014 Top10BestSEOHosting.com is ... researchers have announced that HostGator.com http://secure.hostgator.com/~affiliat/cgi-bin/affiliates/clickthru.cgi?id=seohosts ... current market. Also, they has announced that Bluehost ... , Hostgator, one of the Top 10 ... of cheap Windows hosting, and it offers rich ...
Breaking Medicine News(10 mins):Health News:Expanding Care at the Forefront of Dermatology 2Health News:Profit By Outsourcing Offering Discount for Labor Day on all Web Development Services 2Health News:Transvenous lead extraction clinically successful in 98 percent of cases 2Health News:Transvenous lead extraction clinically successful in 98 percent of cases 3Health News:Top10BestSEOHosting.com: HostGator.com Is The Best Windows Hosting Supplier 2
... Approximately sixty-five state and local public health laboratories ... confirmatory testing of Human Influenza A H1N1 of Swine ... all swine flu specimens had to be sent to ... identifies specimens to the strain level.The rRT-PCR swine flu ...
... Approved Simponi is Expected to Achieve Strong ... a New Report from Decision ResourcesWALTHAM, Mass., ... the world,s leading research and advisory firms ... the availability of Amgen/Wyeth/Takeda,s Enbrel, Centocor/Schering-Plough/Mitsubishi Tanabe,s ...
... Justice grant creates federal-state-local partnership to help fight ... A sweeping $1.1 million U.S. Justice Dept. grant ... prosecution agency to help combat domestic violence and ... State,s Attorney,s Appellate Prosecutor,s office has hired two ...
... promise in study , , THURSDAY, April 30 (HealthDay News) ... multiple sclerosis (MS) drug may give patients more relief ... a new study. , In the study, which included ... selected to receive the steroid drug methylprednisolone in three ...
... After surgery to remove the head of the pancreas, ... in a lower rate of pancreatic fistula, according to ... Center. The research was published in the Journal ... performed as a randomized trial the gold standard ...
... up 266%, , ... Winston-Salem, NC ... that it is expanding its corporate and satellite offices to ... system, VerteLoc™. , , , , ,"We are essentially doubling ...
Cached Medicine News:Health News:Public Health Laboratories To Assume Primary Responsibility for Confirmatory Testing of Swine Flu 2Health News:Driven by Sales of Enbrel, Remicade and Humira, spondyloarthropathies Drug Market Grew to Nearly $2 Billion in 2008 2Health News:Driven by Sales of Enbrel, Remicade and Humira, spondyloarthropathies Drug Market Grew to Nearly $2 Billion in 2008 3Health News:New Illinois Prosecution Unit Helps Protect Women Against Violence 2Health News:Drug Combo May Relieve MS Symptoms 2Health News:Type of connection procedure after pancreatic surgery influenced rate of pancreatic fistula 2Health News:VGI Announces Expansion to Meet Surgeon Demand for the VerteLoc™ Spine Stabilization System 2
(Date:8/29/2014)... The Competitive Intelligence (CI) function is evolving ... leaders who adjust will succeed, and those who don,t ... Practices, LLC study CI leaders from 32 biopharmaceutical organizations ... - Use secondary research whenever possible - it,s effective, ... Internal staff who are creative thinkers provide the CI ...
(Date:8/29/2014)... , Aug. 29, 2014   Mast ... biopharmaceutical company, announced today that Santosh Vetticaden, Chief ... leaving the Company, for personal reasons, in mid-September.  ... Medical Officer of Aires Pharmaceuticals, which Mast acquired ... responsibilities as the Company,s interim Chief Medical Officer.  ...
(Date:8/29/2014)... Research and Markets has announced the addition ... report to their offering. Benefiting ... for medical expenses, the Chinese orthopedic instrument market demand ... CAGR of 19.2% during 2009-2013. Trauma products, spine products ... instruments in China , of which ...
Breaking Medicine Technology:Using the Competitive Intelligence Function to Drive Better Business Decisions in the Pharmaceutical Sector 2Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4China Orthopedic Instrument Industry Report, 2014-2017 2
... of bortezomib-relapsed patient population demonstrates 55% overall response ... 26 Keryx Biopharmaceuticals, Inc. (Nasdaq: ... an ongoing Phase 1/2 study of KRX-0401 (perifosine) ... with relapsed/refractory multiple myeloma. The data, which was ...
... ExonHit Therapeutics,(Alternext: ALEHT) is pleased to announce that clinical ... is progressing well. Patient,enrolment for the Phase IIa trial ... , "The successful completion of ... in the development of EHT 0202, and,provides a clear ...
Cached Medicine Technology:Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting 4ExonHit Therapeutics Reports Advancements in the Clinical Development of EHT 0202, its Phase II Drug for Alzheimer's Disease 2ExonHit Therapeutics Reports Advancements in the Clinical Development of EHT 0202, its Phase II Drug for Alzheimer's Disease 3ExonHit Therapeutics Reports Advancements in the Clinical Development of EHT 0202, its Phase II Drug for Alzheimer's Disease 4
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: